TITLE:
Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections

CONDITION:
Bacteremia

INTERVENTION:
dalbavancin

SUMMARY:

      This is a study to evaluate a new medication dosed once a week in the treatment of bacterial
      infections in the blood from intravenous catheters (CR-BSI). The primary objective is to
      evaluate the efficacy and safety of dalbavancin in the treatment of adults with CR-BSI
      relative to a standard of care treatment, vancomycin.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        -  The patient or his/her legally authorized representative has given informed consent
             by means approved by the investigators IRB/EC;

          -  > 18 years of age;

          -  Had one or more central venous catheters at the time initial signs of infection were
             evident;

          -  Creatinine clearance <50 mL/min;

          -  Bilirubin > 2x the upper limit of normal;

          -  Treatment with an antibiotic effective against Gram-positive bacterial infections for
             more than 24 hours within 48 hours of study medication initiation,

          -  Prolonged antibiotic therapy for CR-BSI anticipated (i.e., >2 weeks)
      
